ROCKVILLE, MARYLAND , August 24, 2026 -According to the latest market study by Fact.MR (Report Code: FACT15845MR), the global Veterinary CRO CDMO Market stood at USD 6.9 billion in the 2025 base year and is projected to expand from USD 7.5 billion in 2026 to USD 16.2 billion by 2036. [Note on Source Data Consistency: The source report lists both a 2025 base-year valuation of USD 6.9 billion and a 2026 forecast starting point of USD 7.5 billion.] This expansion represents a compound annual growth rate (CAGR) of 8.0% across the 2026–2036 forecast timeframe, yielding an absolute opportunity of USD 8.7 billion.
Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15845
Key Market Findings & Executive Overview
The growth of the Veterinary CRO CDMO Market is propelled by an increased shift among animal health sponsors toward outsourcing study design, preclinical safety testing, formulation development, and manufacturing scale-up.
• Base-Year Valuation (2025): USD 6.9 billion
• Forecast Period Opening Value (2026): USD 7.5 billion
• Forecast Period Closing Value (2036): USD 16.2 billion
• Compound Annual Growth Rate (2026–2036): 8.0%
• Absolute Opportunity Growth: USD 8.7 billion
• Core Market Driver: Expansion in livestock health pipelines and heightened regulatory proof requirements prior to product filing.
"Veterinary CRO CDMO growth is expected to depend on animal-specific trial design and dependable service execution," states Shambhu Nath Jha, Principal Consultant at Fact.MR. "Sponsors are expected to prefer partners that reduce approval risk instead of partners that only offer capacity."
Market Growth Drivers & Impact Quantifications
Fact.MR’s research isolates five primary demand drivers along with specific CAGR impact percentages, timeline horizons, and geographic focus areas:
1. Livestock Animal Study Volume (+1.8% CAGR Impact):
o Timeline: Short term (